OA-4 inhibits osteoclast formation and bone resorption via suppressing RANKL induced P38 signaling pathway

Current Medicinal Chemistry

Volumn 21, Issue 5, 2014, Pages 641-649

  Tian, B ^a   Qin, A ^a,b   Shao, Z Y ^c   Jiang, T ^d   Zhai, Z J ^a   Li, H W ^a   Tang, T T ^a   Jiang, Q ^d   Dai, K R ^a   Zheng, M H ^b   Yu, Y P ^c   Zhu, Z A ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ZHEJIANG UNIVERSITY   (China)

^d MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

OA 4; Osteoclast formation; Osteoclastic bone resorption; Osteoporosis; P38 signaling pathway

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; N (3 (CYCLOHEXYLCARBAMOYL) PHENYL) 1H INDOLE 2 CARBOXAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; CYTOTOXICITY ASSAY; DRUG SYNTHESIS; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BENZAMIDES; BONE MARROW CELLS; BONE MATRIX; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; INDOLES; MACROPHAGES; MICE; MICE, INBRED C57BL; MONOCYTES; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84893258507     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990190     Document Type: Article

References (37)

1. Teitelbaum, S.L. Bone resorption by osteoclasts. Science, 2000, 289(5484), 1504-1508.
2. Boyle, W.J.; Simonet, W.S.; Lacey, D.L. Osteoclast differentiation and activation. Nature, 2003, 423(6937), 337-342.
3. Qin, A.; Cheng, T.S.; Pavlos, N.J.; Lin, Z.; Dai, K.R.; Zheng, M.H. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int. J. Biochem. Cell. Biol., 2012, 44(9), 1422-1435.
4. Boyce, B.F.; Rosenberg, E.; de Papp, A.E.; Duong le, T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur. J. Clin. Invest., 2012, 42(12), 1332-1341.
5. Kelemen, E. Osteoclasts and haematopoietic stem cells in developing human bones. Nature, 1986, 323(6090), 743.
6. Asagiri, M.; Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone, 2007, 40(2), 251-264.
7. Suda, T.; Takahashi, N.; Udagawa, N.; Jimi, E.; Gillespie, M.T.; Martin, T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 1999, 20(3), 345-357.
8. Nakashima, T.; Hayashi, M.; Fukunaga, T.; Kurata, K.; Oh-Hora, M.; Feng, J.Q.; Bonewald, L.F.; Kodama, T.; Wutz, A.; Wagner, E.F.; Penninger, J.M.; Takayanagi, H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med., 2011, 17(10), 1231-1234.
9. Armstrong, A.P.; Tometsko, M.E.; Glaccum, M.; Sutherland, C.L.; Cosman, D.; Dougall, W.C. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem., 2002, 277(46), 44347-44356.
10. Novack, D.V. Role of NF-kappaB in the skeleton. Cell. Res., 2011, 21(1), 169-182.
11. Iwasaki, S.; Iguchi, M.; Watanabe, K.; Hoshino, R.; Tsujimoto, M.; Kohno, M. Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J. Biol. Chem., 1999, 274(37), 26503-26510.
12. Raingeaud, J.; Whitmarsh, A.J.; Barrett, T.; Derijard, B.; Davis, R.J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol., 1996, 16(3), 1247-1255.
13. Kyriakis, J.M.; Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev., 2012, 92(2), 689-737.
14. Iotsova, V.; Caamano, J.; Loy, J.; Yang, Y.; Lewin, A.; Bravo, R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med., 1997, 3(11), 1285-1289.
15. David, J.P. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci., 2002, 115(22), 4317-4325.
16. Matsumoto, M.; Sudo, T.; Saito, T.; Osada, H.; Tsujimoto, M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem., 2000, 275(40), 31155-31161.
17. Lee, S.E.; Woo, K.M.; Kim, S.Y.; Kim, H.M.; Kwack, K.; Lee, Z.H.; Kim, H.H. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone, 2002, 30(1), 71-77.
18. Mansky, K.C.; Sankar, U.; Han, J.; Ostrowski, M.C. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J. Biol. Chem., 2002, 277(13), 11077-11083.
19. Troen, B.R. The regulation of cathepsin K gene expression. Ann. N. Y. Acad. Sci., 2006, 1068, 165-172.
20. Li, C.; Yang, Z.; Li, Z.; Ma, Y.; Zhang, L.; Zheng, C.; Qiu, W.; Wu, X.; Wang, X.; Li, H.; Tang, J.; Qian, M.; Li, D.; Wang, P.; Luo, J.; Liu, M. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKLmediated NF-kappaB and MAPK signaling pathways. J. Bone Miner. Res., 2011, 26(3), 644-656.
21. Sipos, W.; Pietschmann, P.; Rauner, M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immunemediated bone and joint diseases. Curr. Med. Chem., 2008, 15(2), 127-136.
22. Qin, A.; Cheng, T.S.; Lin, Z.; Cao, L.; Chim, S.M.; Pavlos, N.J.; Xu, J.; Zheng, M.H.; Dai, K.R. Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS One, 2012, 7(4), e34132.
23. Li, H.; Zhai, Z.; Liu, G.; Tang, T.; Lin, Z.; Zheng, M.; Qin, A.; Dai, K. Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-kappaB and ERK signaling pathways. Biochem. Biophys. Res. Commun., 2013, 430(3), 951-956.
24. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25(4), 402-408.
25. Li, B.; Ling Chau, J.F.; Wang, X.; Leong, W.F. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J. Cell. Biochem., 2011, 112(5), 1229-1242.
26. Maximov, P.Y.; Lee, T.M.; Jordan, V.C. The discovery and development of Selective Estrogen Receptor Modulators (SERMs) for clinical practice. Curr. Clin. Pharmacol., 2012.
27. Brewer, L.; Williams, D.; Moore, A. Current and future treatment options in osteoporosis. Eur. J. Clin. Pharmacol., 2011, 67(4), 321-331.
28. Watts, N.B. Bisphosphonate treatment of osteoporosis. Clin. Geriatr. Med., 2003, 19(2), 395-414.
29. Body, J.J. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone, 2002, 30(5 Suppl), 75S-79S.
30. O'Regan, R.M.; Gradishar, W.J. Selective estrogen-receptor modulators in 2001. Oncology (Williston Park), 2001, 15(9), 1177-1185, 1189-1190; discussion 1190-1174.
31. Visentin, L.; Dodds, R.A.; Valente, M.; Misiano, P.; Bradbeer, J.N.; Oneta, S.; Liang, X.; Gowen, M.; Farina, C. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J. Clin. Invest., 2000, 106(2), 309-318.
32. Petrangolini, G.; Supino, R.; Pratesi, G.; Dal Bo, L.; Tortoreto, M.; Croce, A.C.; Misiano, P.; Belfiore, P.; Farina, C.; Zunino, F. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J. Pharmacol. Exp. Ther., 2006, 318(3), 939-946.
33. Farina, C.; Gagliardi, S.; Rahman, S.S. Azolylbenzamides and Analogues and their Use for Treating Osteoporosis. WO 2001/000587 A1, 2001.
34. Nadler, G.; Morvan, M.; Delimoge, I.; Belfiore, P.; Zocchetti, A.; James, I.; Zembryki, D.; Lee-Rycakzewski, E.; Parini, C.; Consolandi, E.; Gagliardi, S.; Farina, C. (2Z,4E)-5-(5,6-dichloro-2- indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4- pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase. Biorg. Med. Chem. Lett., 1998, 8(24), 3621-3626.
35. Niikura, K.; Nakajima, S.; Takano, M.; Yamazaki, H. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats. Bone, 2007, 40(4), 888-894.
36. Huang, H.; Chang, E.J.; Ryu, J.; Lee, Z.H.; Lee, Y.; Kim, H.H. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem. Biophys. Res. Commun., 2006, 351(1), 99-105.
37. Matsumoto, M.; Sudo, T.; Maruyama, M.; Osada, H.; Tsujimoto, M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett., 2000, 486(1), 23-28.